Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-SofiaWAR:SPH -5.03%67 5-Year Yield-on-Cost % is 5.15 as of Jul. 24, 2026, which is 299% above its 10-year median of 1.29. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.37 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 68 Medical Distribution companies, Sopharma AD-Sofia ranks better than 69.12% on this metric.
Sopharma AD-Sofia's yield on cost for the quarter that ended in Mar. 2026 was 5.15.
The historical rank and industry rank for Sopharma AD-Sofia's 5-Year Yield-on-Cost % or its related term are showing as below:
WAR:SPH'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.44 Med: 1.29 Max: 13.36
Current: 5.15
During the past 13 years, Sopharma AD-Sofia's highest Yield on Cost was 13.36. The lowest was 0.44. And the median was 1.29.
WAR:SPH's 5-Year Yield-on-Cost % is ranked better than 69.12% of 68
companies
in the Medical Distribution industry
Industry Median: 3.39
vs WAR:SPH: 5.15
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sopharma AD-Sofia 5-Year Yield-on-Cost % Related Terms
WAR:SPH vs MCK, CAH, COR: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sopharma AD-Sofia (WAR:SPH) has a 5-Year Yield-on-Cost % of 5.15 as of Jul. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sopharma AD-Sofia and its competitors. This is 299% above median its historical median of 1.29. Over the past decade, Sopharma AD-Sofia's 5-Year Yield-on-Cost % has ranged from 0.44 to 13.36. According to the industry distribution chart, Sopharma AD-Sofia ranks #21 out of 68 companies in the Medical Distribution industry, placing it in the top 30.9%.
Is Sopharma AD-Sofia's 5-Year Yield-on-Cost % too high?
Sopharma AD-Sofia's current 5-Year Yield-on-Cost % of 5.15 is 299% above median its 10-year median of 1.29. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 13.36. The Medical Distribution industry median 5-Year Yield-on-Cost % is 3.39. Sopharma AD-Sofia's value of 5.15 is 51.9% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #21 out of 68 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's 5-Year Yield-on-Cost % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #21 out of 68 companies for 5-Year Yield-on-Cost %. This puts Sopharma AD-Sofia in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 3.39. Sopharma AD-Sofia's value of 5.15 is 51.9% above this benchmark. Historically, Sopharma AD-Sofia's own 5-Year Yield-on-Cost % has ranged from 0.44 to 13.36 over the past decade. While the company's 10-year median is 1.29 vs. the industry median of 3.39, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.39, based on 68 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current 5-Year Yield-on-Cost % of 5.15 is 51.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current 5-Year Yield-on-Cost % is 5.15, which is 299% above median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.37, compared to a current price of zł7.56 — trading 43.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.15, which is 299% above median its 10-year median of 1.29 and 51.9% above the Medical Distribution industry median of 3.39. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current 5-Year Yield-on-Cost % is 5.15 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.56 is trading 43.5% below its estimated GF Value™ of zł13.37.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
5-Year Yield-on-Cost %: 5.15 (299% above median its 10-year median of 1.29)
GF Value™: zł13.37 vs. price of zł7.56 (43.5% below fair value)
Industry Position: 51.9% above the Medical Distribution median (#21 of 68)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
